Sage Journals: Discover world-class research

Abstract

Exposed necrotic alveolar bone is a hallmark of bisphosphonate-related osteonecrosis of the jaw. However, it is unknown whether zoledronate causes soft-tissue damage via adverse actions toward periodontal fibroblasts. We therefore examined whether zoledronate causes a cytotoxic response in fibroblasts isolated from the gingiva and the periodontal ligament. We report that micromolar concentrations of zoledronate and serum-free conditions decreased cell activity, as measured by assays for formazan formation, proliferation, and protein synthesis. Under these conditions, periodontal fibroblasts underwent apoptosis and necrosis, as indicated by cleavage of PARP and membrane disruption, respectively. However, these adverse effects of zoledronate were mitigated by the presence of serum. Moreover, zoledronate bound to calcium phosphate failed to reduce cell activity. Analysis of these data suggests that the cytotoxic responses of periodontal fibroblasts require high concentrations of zoledronate and depend on the in vitro experimental conditions. Whether these findings translate into soft-tissue damage will require further investigation.

Get full access to this article

View all access options for this article.

References

Allen MR, Burr DB (2009). The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data. J Oral Maxillofac Surg 67(5 Suppl):61S–70S.

Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al. (2007). Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–1822.

Chang JT, Green L, Beitz J (2003). Renal failure with the use of zoledronic acid. N Engl J Med 349:1676–1679.

Chen T, Berenson J, Vescio R, Swift R, Gilchick A, Goodin S, et al. (2002). Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol 42:1228–1236.

Corey E, Brown LG, Quinn JE, Poot M, Roudier MP, Higano CS, et al. (2003). Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res 9:295–306; erratum in Clin Cancer Res 9:1574–1575, 2003.

Correia VdeF, Caldeira CL, Marques MM (2006). Cytotoxicity evaluation of sodium alendronate on cultured human periodontal ligament fibroblasts. Dent Traumatol 22:312–317.

Coxon FP, Thompson K, Roelofs AJ, Ebetino FH, Rogers MJ (2008). Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells. Bone 42:848–860.

Cremers SC, Pillai G, Papapoulos SE (2005). Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis. Clin Pharmacokinet 44:551–570.

Dumon JC, Journe F, Kheddoumi N, Lagneaux L, Body JJ (2004). Cytostatic and apoptotic effects of bisphosphonates on prostate cancer cells. Eur Urol 45:521–528.

10.

Dunstan CR, Felsenberg D, Seibel MJ (2007). Therapy insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease. Nat Clin Pract Oncol 4:42–55.

11.

Ibrahim A, Scher N, Williams G, Sridhara R, Li N, Chen G, et al. (2003). Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases. Clin Cancer Res 9:2394–2399.

12.

Kars MD, Iseri OD, Ural AU, Gunduz U (2007). In vitro evaluation of zoledronic acid resistance developed in MCF-7 cells. Anticancer Res 27(6B):4031–4037.

13.

Kellinsalmi M, Mönkkönen H, Mönkkönen J, Leskelä HV, Parikka V, Hämaläinen M, et al. (2005). In vitro comparison of clodronate, pamidronate and zoledronic acid effects on rat osteoclasts and human stem cell-derived osteoblasts. Basic Clin Pharmacol Toxicol 97:382–391.

14.

Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, et al. (2007). Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22:1479–1491.

15.

Kimmel DB (2007). Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates. J Dent Res 86:1022–1033.

16.

Melisi D, Caputo R, Damiano V, Bianco R, Veneziani BM, Bianco AR, et al. (2005). Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer. Endocr Relat Cancer 12:1051–1058.

17.

Nanci A, Bosshardt DD (2006). Structure of periodontal tissues in health and disease. Periodontol 2000 40:11–28.

18.

Patntirapong S, Habibovic P, Hauschka PV (2009). Effects of soluble cobalt and cobalt incorporated into calcium phosphate layers on osteoclast differentiation and activation. Biomaterials 30:548–555.

19.

Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P (2007). A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther 29:1548–1558.

20.

Reid IR, Bolland MJ, Grey AB (2007). Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone 41:318–320.

21.

Reinholz GG, Getz B, Pederson L, Sanders ES, Subramaniam M, Ingle JN, et al. (2000). Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Cancer Res 60:6001–6007.

22.

Roelofs AJ, Thompson K, Gordon S, Rogers MJ (2006). Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res 12(20 Pt 2):6222s–6230s.

23.

Ruggiero SL, Drew SJ (2007). Osteonecrosis of the jaws and bisphosphonate therapy. J Dent Res 86:1013–1021; erratum in J Dent Res 86:1223, 2007.

24.

Russell RG (2007). Bisphosphonates: mode of action and pharmacology. Pediatrics 119(Suppl 2):150–162.

25.

Scheper MA, Badros A, Chaisuparat R, Cullen KJ, Meiller TF (2009). Effect of zoledronic acid on oral fibroblasts and epithelial cells: a potential mechanism of bisphosphonate-associated osteonecrosis. Br J Haematol 144:667–676.

26.

Schindeler A, Little DG (2005). Osteoclasts but not osteoblasts are affected by a calcified surface treated with zoledronic acid in vitro. Biochem Biophys Res Commun 338:710–716.

27.

Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW (2000). Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 82:1459–1468.

28.

Thompson K, Rogers MJ (2004). Statins prevent bisphosphonate-induced gamma, delta-T-cell proliferation and activation in vitro. J Bone Miner Res 19:278–288.

29.

Walter C, Klein MO, Pabst A, Al-Nawas B, Duschner H, Ziebart T (2009). Influence of bisphosphonates on endothelial cells, fibroblasts, and osteogenic cells. Clin Oral Investig. Online March 2009 (in press).

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.63 MB

Is Zoledronate Toxic to Human Periodontal Fibroblasts?

Abstract

Get full access to this article

References

Supplementary Material